SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

InspireMD, Inc. (NSPR) News

Follow InspireMD, Inc. (NSPR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol NSPR Asset equity Sector Markets 90 days 10 Last 0.6183 Updated Oct 29, 2026, 12:01 PM UTC Open live news feed Open NSPR chart & news
M InspireMD Director Paul Stuka Acquires $17,400 in Shares Director Paul Stuka acquired $17,400 in InspireMD common shares. EQUITY | Nov 19, 2026, 09:06 PM UTC M InspireMD to Announce Third-Quarter 2026 Results InspireMD says it will announce its third-quarter 2026 financial results. EQUITY | Oct 29, 2026, 12:01 PM UTC M InspireMD lowers warrant exercise price to $0.7674 InspireMD amended certain Series J and Series K warrant terms, setting the exercise price to $0.7674 for 50% of shares under amending Series J warrants and for all shares under amending Series K warrants. EQUITY | Sep 21, 2026, 01:14 PM UTC L NSPR - InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million NSPR - InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million NEWS | Sep 21, 2026, 01:00 PM UTC H Full Transcript: InspireMD Q2 2026 Earnings Call InspireMD (NASDAQ: NSPR ) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you APIs. For real-time LIVE | Sep 17, 2026, 09:42 AM UTC L NSPR: Innovative carotid stent technology is set to disrupt a rapidly expanding U.S. vascular market A novel carotid stent with a 20-micron mesh is driving superior clinical outcomes and rapid adoption in a $1 billion U.S. market, supported by strong trial results, recent CMS reimbursement, and robust funding. Regulator NEWS | Sep 14, 2026, 10:26 PM UTC L NSPR: Innovative carotid stent technology is set to transform stroke prevention and capture U.S. market share A novel carotid stent with a 20-micron mesh is driving best-in-class outcomes and rapid adoption in a $1B U.S. market, supported by strong clinical evidence, recent CMS reimbursement, and robust funding. TCAR and CAS mar REGULATION | Sep 14, 2026, 10:19 PM UTC L InspireMD board compensation committee approves inducement grants InspireMD said its Board of Directors’ Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 04, 2026, 08:07 PM UTC L NSPR/InspireMD announces inducement grants under Nasdaq Rule 5635(c)(4) InspireMD announced inducement grants under Nasdaq Listing Rule 5635(c)(4). EQUITY | Sep 04, 2026, 08:01 PM UTC L InspireMD plans conference presentation at H.C. Wainwright event Monday InspireMD said it plans to present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday. EQUITY | Sep 03, 2026, 12:08 PM UTC L NSPR - InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference NSPR - InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference EQUITY | Sep 03, 2026, 12:00 PM UTC L InspireMD (NSPR) reports second-quarter 2026 financial results InspireMD (NSPR) reports its second-quarter 2026 financial results, according to TradeXchange Newsdesk, with no additional figures or catalysts provided in the source text. EARNINGS | Aug 17, 2026, 11:00 AM UTC M NSPR Appoints Kathleen Kennedy NSPR appoints new sales and marketing leader EQUITY | Jul 30, 2026, 08:01 PM UTC